1932

Abstract

The substantial increase in life expectancy of men has focused growing attention on quality-of-life issues associated with reproductive aging. Serum total and free testosterone levels in men, after reaching a peak in the second and third decade of life, decline gradually with advancing age. The trajectory of age-related decline is affected by comorbid conditions, adiposity, medications, and genetic factors. Testosterone treatment of older men with low testosterone levels improves overall sexual activity, sexual desire, and erectile function; improves areal and volumetric bone density, as well as estimated bone strength in the spine and the hip; corrects unexplained anemia of aging; increases skeletal muscle mass, strength and power, self-reported mobility, and some measures of physical function; and modestly improves depressive symptoms. The long-term effects of testosterone on major cardiovascular events and prostate cancer risk remain unclear. The Endocrine Society recommends against testosterone therapy of all older men with low testosterone levels but suggests consideration of treatment on an individualized basis in men who have consistently low testosterone levels and symptoms or conditions suggestive of testosterone deficiency.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-050219-034711
2021-01-27
2024-06-22
Loading full text...

Full text loading...

/deliver/fulltext/med/72/1/annurev-med-050219-034711.html?itemId=/content/journals/10.1146/annurev-med-050219-034711&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Bhasin S, Brito JP, Cunningham GR et al. 2018. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 103:1715–44
    [Google Scholar]
  2. 2. 
    Nguyen CP, Hirsch MS, Moeny D et al. 2015. Testosterone and “age-related hypogonadism”—FDA concerns. N. Engl. J. Med. 373:689–91
    [Google Scholar]
  3. 3. 
    Bhasin S, Pencina M, Jasuja GK et al. 2011. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J. Clin. Endocrinol. Metab. 96:2430–39
    [Google Scholar]
  4. 4. 
    Harman SM, Metter EJ, Tobin JD et al. 2001. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86:724–31
    [Google Scholar]
  5. 5. 
    Mohr BA, Bhasin S, Link CL et al. 2006. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur. J. Endocrinol. 155:443–52
    [Google Scholar]
  6. 6. 
    Spitzer M, Huang G, Basaria S et al. 2013. Risks and benefits of testosterone therapy in older men. Nat. Rev. Endocrinol. 9:414–24
    [Google Scholar]
  7. 7. 
    Wu FC, Tajar A, Pye SR et al. 2008. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J. Clin. Endocrinol. Metab. 93:2737–45
    [Google Scholar]
  8. 8. 
    Coviello AD, Lakshman K, Mazer NA, Bhasin S 2006. Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. J. Clin. Endocrinol. Metab. 91:4669–75
    [Google Scholar]
  9. 9. 
    Harman SM, Tsitouras PD. 1980. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J. Clin. Endocrinol. Metab. 51:35–40
    [Google Scholar]
  10. 10. 
    Harman SM, Tsitouras PD, Costa PT, Blackman MR 1982. Reproductive hormones in aging men. II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone-releasing hormone. J. Clin. Endocrinol. Metab. 54:547–51
    [Google Scholar]
  11. 11. 
    Mulligan T, Iranmanesh A, Johnson ML et al. 1997. Aging alters feed-forward and feedback linkages between LH and testosterone in healthy men. Am. J. Physiol. 273:R1407–13
    [Google Scholar]
  12. 12. 
    Pincus SM, Mulligan T, Iranmanesh A et al. 1996. Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. PNAS 93:14100–5
    [Google Scholar]
  13. 13. 
    Winters SJ, Sherins RJ, Troen P 1984. The gonadotropin-suppressive activity of androgen is increased in elderly men. Metabolism 33:1052–59
    [Google Scholar]
  14. 14. 
    Bremner WJ, Vitiello MV, Prinz PN 1983. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. 56:1278–81
    [Google Scholar]
  15. 15. 
    Tajar A, Forti G, O'Neill TW et al. 2010. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J. Clin. Endocrinol. Metab. 95:1810–18
    [Google Scholar]
  16. 16. 
    O'Connor DB, Lee DM, Corona G et al. 2011. The relationships between sex hormones and sexual function in middle-aged and older European men. J. Clin. Endocrinol. Metab. 96:E1577–87
    [Google Scholar]
  17. 17. 
    Wu FC, Tajar A, Beynon JM et al. 2010. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 363:123–35
    [Google Scholar]
  18. 18. 
    Baumgartner RN, Waters DL, Gallagher D et al. 1999. Predictors of skeletal muscle mass in elderly men and women. Mech. Ageing Dev. 107:123–36
    [Google Scholar]
  19. 19. 
    Krasnoff JB, Basaria S, Pencina MJ et al. 2010. Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. J. Clin. Endocrinol. Metab. 95:2790–99
    [Google Scholar]
  20. 20. 
    Roy TA, Blackman MR, Harman SM et al. 2002. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am. J. Physiol. Endocrinol. Metab. 283:E284–94
    [Google Scholar]
  21. 21. 
    Schaap LA, Pluijm SM, Deeg DJ et al. 2008. Low testosterone levels and decline in physical performance and muscle strength in older men: findings from two prospective cohort studies. Clin. Endocrinol. 68:42–50
    [Google Scholar]
  22. 22. 
    Amin S, Zhang Y, Sawin CT et al. 2000. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann. Intern. Med. 133:951–63
    [Google Scholar]
  23. 23. 
    Khosla S, Melton LJ3rd, Robb RA et al. 2005. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J. Bone Miner. Res. 20:730–40
    [Google Scholar]
  24. 24. 
    Amin S, Zhang Y, Felson DT et al. 2006. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am. J. Med. 119:426–33
    [Google Scholar]
  25. 25. 
    Mellstrom D, Vandenput L, Mallmin H et al. 2008. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J. Bone Miner. Res. 23:1552–60
    [Google Scholar]
  26. 26. 
    Finkelstein JS, Lee H, Leder BZ et al. 2016. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J. Clin. Investig. 126:1114–25
    [Google Scholar]
  27. 27. 
    Bhasin S, Jasjua GK, Pencina M et al. 2011. Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the Framingham Heart Study. Diabetes Care 34:2464–70
    [Google Scholar]
  28. 28. 
    Ding EL, Song Y, Malik VS, Liu S 2006. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295:1288–99
    [Google Scholar]
  29. 29. 
    Lakshman KM, Bhasin S, Araujo AB 2010. Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. J. Gerontol. A Biol. Sci. Med. Sci. 65:503–9
    [Google Scholar]
  30. 30. 
    Araujo AB, Dixon JM, Suarez EA et al. 2011. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96:3007–19
    [Google Scholar]
  31. 31. 
    Khazai B, Golden SH, Colangelo LA et al. 2016. Association of endogenous testosterone with subclinical atherosclerosis in men: the Multi-Ethnic Study of Atherosclerosis. Clin. Endocrinol. 84:700–7
    [Google Scholar]
  32. 32. 
    Liu XA, Zhu LQ, Zhang Q et al. 2008. Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A. Neurochem. Res. 33:1811–20
    [Google Scholar]
  33. 33. 
    Oikawa N, Ogino K, Masumoto T et al. 2010. Gender effect on the accumulation of hyperphosphorylated tau in the brain of locus-ceruleus-injured APP-transgenic mouse. Neurosci. Lett. 468:243–47
    [Google Scholar]
  34. 34. 
    Rosario ER, Carroll J, Pike CJ 2010. Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Res 1359:281–90
    [Google Scholar]
  35. 35. 
    Hogervorst E, Combrinck M, Smith AD 2003. Testosterone and gonadotropin levels in men with dementia. Neuro Endocrinol. Lett. 24:203–8
    [Google Scholar]
  36. 36. 
    Hogervorst E, Lehmann DJ, Warden DR et al. 2002. Apolipoprotein E epsilon4 and testosterone interact in the risk of Alzheimer's disease in men. Int. J. Geriatr. Psychiatry 17:938–40
    [Google Scholar]
  37. 37. 
    Moffat SD, Zonderman AB, Metter EJ et al. 2002. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J. Clin. Endocrinol. Metab. 87:5001–7
    [Google Scholar]
  38. 38. 
    Moffat SD, Zonderman AB, Metter EJ et al. 2004. Free testosterone and risk for Alzheimer disease in older men. Neurology 62:188–93
    [Google Scholar]
  39. 39. 
    Rosario ER, Chang L, Stanczyk FZ, Pike CJ 2004. Age-related testosterone depletion and the development of Alzheimer disease. JAMA 292:1431–32
    [Google Scholar]
  40. 40. 
    Lv W, Du N, Liu Y et al. 2016. Low testosterone level and risk of Alzheimer's disease in the elderly men: a systematic review and meta-analysis. Mol. Neurobiol. 53:2679–84
    [Google Scholar]
  41. 41. 
    Hier DB, Crowley WF Jr 1982. Spatial ability in androgen-deficient men. N. Engl. J. Med. 306:1202–5
    [Google Scholar]
  42. 42. 
    Barrett-Connor E, Goodman-Gruen D, Patay B 1999. Endogenous sex hormones and cognitive function in older men. J. Clin. Endocrinol. Metab. 84:3681–85
    [Google Scholar]
  43. 43. 
    Muller M, Aleman A, Grobbee DE et al. 2005. Endogenous sex hormone levels and cognitive function in aging men: Is there an optimal level. Neurology 64:866–71
    [Google Scholar]
  44. 44. 
    Martin DM, Wittert G, Burns NR et al. 2007. Testosterone and cognitive function in ageing men: data from the Florey Adelaide Male Ageing Study (FAMAS). Maturitas 57:182–94
    [Google Scholar]
  45. 45. 
    Matousek RH, Sherwin BB. 2010. Sex steroid hormones and cognitive functioning in healthy, older men. Horm. Behav. 57:352–59
    [Google Scholar]
  46. 46. 
    Roddam AW, Allen NE, Appleby P, Key TJ 2008. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl. Cancer Inst. 100:170–83
    [Google Scholar]
  47. 47. 
    Lee JH, Kim Y, Park YW, Lee DG 2014. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men. J. Sex. Med. 11:1309–15
    [Google Scholar]
  48. 48. 
    Ruth KS, Day FR, Tyrrell J et al. 2020. Using human genetics to understand the disease impacts of testosterone in men and women. Nat. Med. 26:252–58
    [Google Scholar]
  49. 49. 
    Eriksson AL, Perry JRB, Coviello AD et al. 2018. Genetic determinants of circulating estrogen levels and evidence of a causal effect of estradiol on bone density in men. J. Clin. Endocrinol. Metab. 103:991–1004
    [Google Scholar]
  50. 50. 
    Brock G, Heiselman D, Maggi M et al. 2016. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J. Urol. 195:699–705
    [Google Scholar]
  51. 51. 
    Steidle C, Schwartz S, Jacoby K et al. 2003. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. 88:2673–81
    [Google Scholar]
  52. 52. 
    Deleted in proof
  53. 53. 
    Snyder PJ, Bhasin S, Cunningham GR et al. 2016. Effects of testosterone treatment in older men. N. Engl. J. Med. 374:611–24
    [Google Scholar]
  54. 54. 
    Snyder PJ, Bhasin S, Cunningham GR et al. 2018. Lessons from the testosterone trials. Endocr. Rev. 39:369–86
    [Google Scholar]
  55. 55. 
    Cunningham GR, Stephens-Shields AJ, Rosen RC et al. 2016. Testosterone treatment and sexual function in older men with low testosterone levels. J. Clin. Endocrinol. Metab. 101:3096–104
    [Google Scholar]
  56. 56. 
    Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N et al. 2018. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab. 2018: 10.1210/jc.2018-00404
    [Google Scholar]
  57. 57. 
    Kwan M, Greenleaf WJ, Mann J et al. 1983. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J. Clin. Endocrinol. Metab. 57:557–62
    [Google Scholar]
  58. 58. 
    Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I 1990. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J. Clin. Endocrinol. Metab. 70:792–97
    [Google Scholar]
  59. 59. 
    Buena F, Swerdloff RS, Steiner BS et al. 1993. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil. Steril. 59:1118–23
    [Google Scholar]
  60. 60. 
    Finkelstein JS, Lee H, Burnett-Bowie SA et al. 2013. Gonadal steroids and body composition, strength, and sexual function in men. N. Engl. J. Med. 369:1011–22
    [Google Scholar]
  61. 61. 
    Basaria S, Harman SM, Travison TG et al. 2015. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA 314:570–81
    [Google Scholar]
  62. 62. 
    Spitzer M, Basaria S, Travison TG et al. 2012. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann. Intern. Med. 157:681–91
    [Google Scholar]
  63. 63. 
    Bhasin S, Woodhouse L, Casaburi R et al. 2005. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J. Clin. Endocrinol. Metab. 90:678–88
    [Google Scholar]
  64. 64. 
    Storer TW, Basaria S, Traustadottir T et al. 2017. Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men. J. Clin. Endocrinol. Metab. 102:583–93
    [Google Scholar]
  65. 65. 
    Sinha-Hikim I, Artaza J, Woodhouse L et al. 2002. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. Endocrinol. Metab. 283:E154–64
    [Google Scholar]
  66. 66. 
    Bhasin S, Apovian CM, Travison TG et al. 2018. Effect of protein intake on lean body mass in functionally limited older men: a randomized clinical trial. JAMA Intern. Med. 178:530–41
    [Google Scholar]
  67. 67. 
    Blackman MR, Sorkin JD, Munzer T et al. 2002. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288:2282–92
    [Google Scholar]
  68. 68. 
    Bhasin S, Ellenberg SS, Storer TW et al. 2018. Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes Endocrinol 6:879–90
    [Google Scholar]
  69. 69. 
    Traustadottir T, Harman SM, Tsitouras P et al. 2018. Long-term testosterone supplementation in older men attenuates age-related decline in aerobic capacity. J. Clin. Endocrinol. Metab. 103:2861–69
    [Google Scholar]
  70. 70. 
    Tracz MJ, Sideras K, Bolona ER et al. 2006. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J. Clin. Endocrinol. Metab. 91:2011–16
    [Google Scholar]
  71. 71. 
    Snyder PJ, Kopperdahl DL, Stephens-Shields AJ et al. 2017. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern. Med. 177:471–79
    [Google Scholar]
  72. 72. 
    Bhasin S, Seidman S. 2019. Testosterone treatment of depressive disorders in men: too much smoke, not enough high-quality evidence. JAMA Psychiatry 76:9–10
    [Google Scholar]
  73. 73. 
    Seidman SN, Araujo AB, Roose SP, McKinlay JB 2001. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol. Psychiatry 50:371–76
    [Google Scholar]
  74. 74. 
    Seidman SN, Spatz E, Rizzo C, Roose SP 2001. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J. Clin. Psychiatry 62:406–12
    [Google Scholar]
  75. 75. 
    Pope HG Jr., Amiaz R, Brennan BP et al. 2010. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J. Clin. Psychopharmacol. 30:126–34
    [Google Scholar]
  76. 76. 
    Seidman SN, Orr G, Raviv G et al. 2009. Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial. J. Clin. Psychopharmacol. 29:216–21
    [Google Scholar]
  77. 77. 
    Shores MM, Kivlahan DR, Sadak TI et al. 2009. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J. Clin. Psychiatry 70:1009–16
    [Google Scholar]
  78. 78. 
    Walther A, Breidenstein J, Miller R 2019. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry 76:31–40
    [Google Scholar]
  79. 79. 
    Corona G, Giagulli VA, Maseroli E et al. 2016. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J. Endocrinol. Investig. 39:967–81
    [Google Scholar]
  80. 80. 
    Woodhouse LJ, Gupta N, Bhasin M et al. 2004. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J. Clin. Endocrinol. Metab. 89:718–26
    [Google Scholar]
  81. 81. 
    Yialamas MA, Dwyer AA, Hanley E et al. 2007. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 92:4254–59
    [Google Scholar]
  82. 82. 
    Jones TH, Arver S, Behre HM et al. 2011. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34:828–37
    [Google Scholar]
  83. 83. 
    Hua JT, Hildreth KL, Pelak VS 2016. Effects of testosterone therapy on cognitive function in aging: a systematic review. Cogn. Behav. Neurol. 29:122–38
    [Google Scholar]
  84. 84. 
    Cherrier MM, Craft S, Matsumoto AH 2003. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J. Androl. 24:568–76
    [Google Scholar]
  85. 85. 
    Lu PH, Masterman DA, Mulnard R et al. 2006. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch. Neurol. 63:177–85
    [Google Scholar]
  86. 86. 
    Kathrins M, Doersch K, Nimeh T et al. 2016. The relationship between testosterone-replacement therapy and lower urinary tract symptoms: a systematic review. Urology 88:22–32
    [Google Scholar]
  87. 87. 
    Kohn TP, Mata DA, Ramasamy R, Lipshultz LI 2016. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur. Urol. 69:1083–90
    [Google Scholar]
  88. 88. 
    Liverman CT, Blazer DGeds. 2004. Testosterone and Aging: Clinical Research Directions Washington, DC: Inst. Med.
    [Google Scholar]
  89. 89. 
    Bhasin S, Singh AB, Mac RP et al. 2003. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J. Androl. 24:299–311
    [Google Scholar]
  90. 90. 
    Budoff MJ, Ellenberg SS, Lewis CE et al. 2017. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 317:708–16
    [Google Scholar]
  91. 91. 
    Corona G, Rastrelli G, Di Pasquale G et al. 2018. Testosterone and cardiovascular risk: meta-analysis of interventional studies. J. Sex. Med. 15:820–38
    [Google Scholar]
  92. 92. 
    Finkle WD, Greenland S, Ridgeway GK et al. 2014. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS ONE 9:e85805
    [Google Scholar]
  93. 93. 
    Onasanya O, Iyer G, Lucas E et al. 2016. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. Lancet Diabetes Endocrinol 4:943–56
    [Google Scholar]
  94. 94. 
    Shores MM, Smith NL, Forsberg CW et al. 2012. Testosterone treatment and mortality in men with low testosterone levels. J. Clin. Endocrinol. Metab. 97:2050–58
    [Google Scholar]
  95. 95. 
    Vigen R, O'Donnell CI, Baron AE et al. 2013. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310:1829–36
    [Google Scholar]
  96. 96. 
    FDA (Food Drug Adm.) 2014. Citizen petition denial response from FDA CDER to public citizen. http://www.regulations.gov/document?D=FDA-2014-P-0258-0003
  97. 97. 
    Houghton DE, Alsawas M, Barrioneuvo P et al. 2018. Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis. Thromb. Res. 172:94–103
    [Google Scholar]
  98. 98. 
    Glueck CJ, Goldenberg N, Wang P 2018. Testosterone therapy, thrombophilia, venous thromboembolism, and thrombotic events. J. Clin. Med. 8:11
    [Google Scholar]
  99. 99. 
    Ory J, Flannigan R, Lundeen C et al. 2016. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J. Urol. 196:1082–89
    [Google Scholar]
  100. 100. 
    Cunningham GR, Ellenberg SS, Bhasin S et al. 2019. Prostate-specific antigen levels during testosterone treatment of hypogonadal older men: data from a controlled trial. J. Clin. Endocrinol. Metab. 104:6238–46
    [Google Scholar]
/content/journals/10.1146/annurev-med-050219-034711
Loading
/content/journals/10.1146/annurev-med-050219-034711
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error